Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Darolutamide in Hepatic and Renal Impairment
NCT02894385Phase 1Completed
- Sponsor
- Bayer
- Start
- Sep 2016
- Primary completion
- Apr 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of darolutamide in prostate cancer (PCa) (3 arms), sponsored by Bayer. Primary endpoints: Area under the concentration-time curve from time zero to 48 hours and Maximum drug concentration. Started Sep 2016; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02894385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02894385.